STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences Inc - CSTL STOCK NEWS

Welcome to our dedicated news page for Castle Biosciences (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Castle Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Castle Biosciences's position in the market.

News
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) granted restricted stock units to 52 employees covering 170,913 shares of common stock as an inducement material to their entering into employment. The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through each applicable vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) published a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that revealed 82.4% of NPs/PAs using DecisionDx-Melanoma in clinical practice would change patient treatment plans based on high-risk test results in thin melanoma tumors. Similarly, 81.3% would alter treatment plans for Stage 1 tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
News
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) presented robust data at the 2023 ASDS Annual Meeting, reinforcing the clinical validity and utility of its skin cancer test portfolio. The data highlighted the DecisionDx-Melanoma and DecisionDx-SCC tests, demonstrating their ability to predict tumor recurrence in stage I cutaneous melanoma and identify patients at less than 5% risk of sentinel lymph node biopsy metastasis. The DecisionDx-SCC test was also shown to reduce healthcare costs and improve metastatic risk assessment for cutaneous squamous cell carcinoma patients. MyPath Melanoma testing was presented as a valuable tool in the diagnostic work-up of ambiguous melanocytic neoplasms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
News
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) Earns National Recognition and Three Top Workplaces Culture Excellence Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
News
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces data from a study demonstrating the consistent impact of IDgenetix on medication response and remission rates in patients with major depressive disorder (MDD). Results show that patients whose medication management was guided by IDgenetix were 2.65 times more likely to achieve remission of depressive symptoms compared to patients whose medication management was not guided by the test. The study compared clinical outcome results from a multi-center randomized controlled trial (RCT) to real-world evidence (RWE) from a single-center, non-randomized, open-label study. Response and remission rates for patients with moderate to severe MDD were analyzed, showing strong alignment between both studies. The impact of drug-drug interactions (DDI) and lifestyle factors on the test results was also highlighted, indicating the unique aspects of IDgenetix.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
News
Castle Biosciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) to Present Company Overview at Investor Conferences in November 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
News
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
Rhea-AI Summary
Castle Biosciences, Inc. announced new discovery data from a study exploring the potential for developing a complementary test to evaluate small, suspicious lesions of uncertain malignant potential in patients' eyes. The data will be presented at the 2023 American Academy of Ophthalmology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
-
News
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
Rhea-AI Summary
Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as differentiate between atopic dermatitis, psoriasis, and mycosis fungoides skin lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
-
News
Castle Biosciences Reports Third Quarter 2023 Results
Rhea-AI Summary
Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. Gross margin for Q3 was 78% and adjusted gross margin was 81%. Net cash provided by operations was $5.0 million, and adjusted EBITDA was $6.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
earnings
News
Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
Rhea-AI Summary
Castle Biosciences will highlight the risk stratification capabilities of its TissueCypher test for patients with Barrett's esophagus at the ACG 2023 Annual Scientific Meeting. The test can identify higher- and lower-risk subsets of patients, providing objective risk stratification that can help guide patient care and potentially prevent cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
conferences
Stock CSTL logo
Castle Biosciences Inc

Nasdaq:CSTL

CSTL Rankings

#2895 Ranked by Market Cap
#4637 Ranked by Stock Gains
N/A Ranked by Dividends

CSTL Stock Data

553.40M
26.64M
4.28%
89.75%
5.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Friendswood

About CSTL

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.